Lurbinectedin - Generic Drug Details

What are the generic sources for lurbinectedin and what is the scope of freedom to operate?

Lurbinectedin is the generic ingredient in one branded drug marketed by Jazz and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lurbinectedin has sixty-four patent family members in thirty-four countries.

One supplier is listed for this compound.

Summary for lurbinectedin

International Patents:	64
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	32
Clinical Trials:	52
Patent Applications:	664
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for lurbinectedin
What excipients (inactive ingredients) are in lurbinectedin?	lurbinectedin excipients list
DailyMed Link:	lurbinectedin at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for lurbinectedin

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for lurbinectedin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AbbVie	PHASE3
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	PHASE1
Sichuan University	PHASE2

See all lurbinectedin clinical trials

Pharmacology for lurbinectedin

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Anatomical Therapeutic Chemical (ATC) Classes for lurbinectedin

L01XX	Other antineoplastic agents
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for LURBINECTEDIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZEPZELCA	Powder for Injection	lurbinectedin	4 mg/vial	213702	5	2024-06-17

US Patents and Regulatory Information for lurbinectedin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes			Y	Y

International Patents for lurbinectedin

Country	Patent Number	Title	Estimated Expiration
Chile	2022001342
Israel	293128
Jordan	P20220118	طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين (METHODS OF TREATING SMALL CELL LUNG CANCER WITH LURBINECTEDIN FORMULATIONS)
China	100334094
Colombia	2022008437
Australia	2025203941

Market Dynamics and Financial Trajectory for Lurbinectedin

Last updated: February 14, 2026

Overview
Lurbinectedin is an oncology drug developed by PharmaMar, primarily indicated for small cell lung carcinoma (SCLC). It functions as a selective inhibitor of oncogenic transcription, interfering with tumor growth. Market entry and sales performance are influenced by regulatory approvals, competitive landscape, and emerging clinical data.

Regulatory Landscape
Lurbinectedin received accelerated approval from the US Food and Drug Administration (FDA) in June 2020 for relapsed SCLC, based on response rates rather than overall survival data. The approval was contingent on confirming benefit in confirmatory trials. European Medicines Agency (EMA) granted orphan designation but has not yet approved the drug for market. Regulatory hesitations and ongoing trials impact its commercial potential.

Market Size and Segments
Estimated global SCLC market:

• 2022: $700 million
• Projected to reach $1.2 billion by 2030 (CAGR: 6.0%) due to increased diagnosis and treatment approval.

Key segments:

• First-line treatment (limited; chemotherapy remains standard)
• Relapsed SCLC (primary target for lurbinectedin)

Competitive Landscape
Lurbinectedin competes mainly with chemotherapy agents and emerging immunotherapies. Key competitors include:

• Topotecan, approved for recurrent SCLC
• Lurbinectedin’s potential combined with immunotherapy (e.g., pembrolizumab)
• Investigational agents with novel mechanisms, such as DLL3-targeted therapies and ADCs

Clinical and Developmental Pipeline
Lurbinectedin’s efficacy in combination regimens is under active investigation. Trials include:

• Phase III studies combining with atezolizumab (PD-L1 inhibitor)
• Trials assessing use in other solid tumors: ovarian, breast, and soft tissue sarcomas

Financial Trajectory and Revenue Projections
Initial revenues:

• 2021: approximately $10 million (launch phase)
• 2022: $25 million, driven by US sales launch and expansion efforts

Forecasts (assuming accelerated uptake):	Year	Revenue ($ millions)	Key Assumptions
2023	50-75	Expanded approval, increased adoption in relapsed SCLC
2025	150-200	Broadened use, successful combination trials, geographic expansion
2030	400-600	Significant market penetration, new indications, and longer-term survival data

Risks:

• Dependence on confirmatory trial outcomes
• Competition from emerging therapies and new standards of care
• Pricing pressures and reimbursement challenges

Key Market Factors

• Adoption hinges on demonstrated survival benefit and manageable safety profile.
• Strategic partnerships or licensing agreements could enhance manufacturing and distribution.
• US and European regulatory decisions heavily influence revenues.

Summary
Lurbinectedin's market journey remains cautious, dependent on trial results and regulatory stances. Although initial sales are modest, future growth prospects are significant if combination strategies and additional indications expand the drug’s utility. The drug’s financial trajectory is optimistic but remains contingent on clinical and regulatory milestones.

---

Key Takeaways

• Lurbinectedin received accelerated FDA approval for relapsed SCLC but lacks full regulatory endorsement globally.
• The global SCLC market is projected to grow at 6% annually, presenting expansion opportunities.
• Revenue growth depends on clinical success in combination trials and approval for additional indications.
• Competitive pressures from existing chemotherapies and novel immunotherapies pose ongoing challenges.
• Long-term profitability hinges on confirmatory trial outcomes, regulatory clarity, and market acceptance.

---

FAQs

1. What is the primary indication for lurbinectedin?
   It is primarily approved for relapsed small cell lung carcinoma (SCLC).

2. When did FDA approve lurbinectedin?
   June 2020, via accelerated approval based on response rates.

3. What are the main competitors to lurbinectedin?
   Topotecan and emerging immunotherapy combination regimens.

4. What factors influence the drug’s revenue growth?
   Clinical trial results, regulatory decisions, adoption rates, and pipeline expansion.

5. Are there prospects beyond SCLC?
   Trials are ongoing for ovarian, breast, and soft tissue sarcomas, which could diversify revenue streams.

---

Citations
[1] PharmaMar official announcements and FDA approval documents.
[2] Market research reports on oncology drug markets.
[3] Clinical trial registries and published study results.